Research Journal of Pharmacy and Technology
SCOPUS
  • Year: 2021
  • Volume: 14
  • Issue: 6

Acute and sub-acute toxicity study of amrtadi churna

  • Author:
  • Sangeeta Mukhi1, Anindya Bose1,*, Dilip Kumar Das2, Sitansu Kumar Panda3, Debahuti Mohapatra4, S. Latha5, Ashok Kumar Balaraman6
  • Total Page Count: 8
  • Page Number: 3111 to 3118

1Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Kalinga Nagar, Bhubaneswar - 751003, Orissa, India

2Department of Pathology, Hi-Tech Medical College, Bhubaneswar, Orissa, India

3Department of Anatomy, Institute of Medical Sciences and SUM Hospital, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, Orissa, India

4Department of Pathology, Institute of Medical Sciences and SUM Hospital, Siksha ‘O’ Anusandhan (Deemed to be University), Kalinga Nagar, Bhubaneswar, Orissa, India

5Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational Research, Anna University, Bharathidasan Institute of Technology Campus, Tiruchirappalli, Tamil Nadu, India

6Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia

*Corresponding Author E-mail: anindyabose_in@yahoo.com

Online published on 25 August, 2021.

Abstract

Amrtadi Churna is an Ayurvedic polyherbal formulation containing three herbs viz., Amalaki (Emblica officinalis), Gokshur (Tribulus terrestris) and Guduchi (Tinospora cordifolia). It is prescribed in India for immunomodulation and treating hyperacidity. The present work reports the acute and sub-acute toxicity assessment of Amrtadi Churna on experimental animals to rule whether it might produce toxicity on herb-herb interactions by combining its ingredient. The results showed that, the single administration of high dose (5000 mg/kg) of the Churna neither induced mortality nor any adverse toxicity signs in rats, suggesting its practically non-toxic nature in the therapeutic doses. Sub-acute toxicity testing results of hematology, serum biochemistry and organ histology showed that the product did not induce any toxic signs at the tested dose levels. However, it produced an apparently harmless hyperbilirubinemia without any signs of liver damage. There were no major gender specific variations except a few hematological parameters. It was concluded that, Amrtadi Churna could be relatively safe at therapeutic dose levels, ruling out any serious side effects by the interaction of its three herbal ingredients.

Keywords

Churna, Herb-herb interaction, HPLC fingerprinting, Hematology, Serum biochemistry, Histopathology